A Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Vertex Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: VX-702

Study type: Interventional

Funder types: Industry

Identifiers

NCT00395577

VX06-702-304

Details and patient eligibility

About

The purpose of this study is to assess the safety and effects of VX-702 in subjects with moderate to severe rheumatoid arthritis and who are taking the drug methotrexate.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients 18 to 75 years of age with active RA
• Must have been taking MTX for at least 6 months
• No concurrent DMARD treatment (other than a stable dose of MTX)

Exclusion criteria

• Planned major surgery (e.g., joint replacement) within the duration of the treatment period of the study
• Treated with intra-articular injections of corticosteroids within 28 days prior to Day 1

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind